ITEM 1.01 Entry into a Material Definitive Agreement
On June 30, 2023, Telesis Bio Inc. (the Company) entered into (i) Amendment No. 2 to Credit, Security and Guaranty Agreement (Term Loan) (the Term Loan Second Amendment), which amends that certain Credit, Security and Guaranty Agreement (Term Loan), dated as of August 9, 2022 (as amended, restated, supplemented or otherwise modified from time to time, the Term Loan Agreement), among the Company, EtonBio, Inc., a California corporation and the Company’s wholly-owned subsidiary (EtonBio and together with the Company, the Borrowers), certain subsidiaries of the Company that may become party thereto from time to time as borrowers or guarantors, the lenders party thereto from time to time (collectively, the Term Loan Lenders) and MidCap Financial Trust, as administrative agent (the Term Agent), and (ii) Amendment No. 2 to Credit, Security and Guaranty Agreement (Revolving Loan) (the Revolving Loan Second Amendment, and together with the Term Loan Second Amendment, the Second Amendments), which amends that certain Credit, Security and Guaranty Agreement (Revolving Loan), dated as of August 9, 2022 (as amended, restated, supplement or otherwise modified from time to time, the Revolving Loan Agreement, and together with the Term Loan Agreement, the Loan Agreements) among the Company, EtonBio, certain subsidiaries of the Company that may become party thereto from time to time as borrowers or guarantors, the lenders party thereto from time to time (collectively, the Revolving Loan Lenders, and together with the Term Loan Lenders, the Lenders) and MidCap Funding IV Trust, as administrative agent (the Revolving Agent).
The Term Loan Second Amendment, among other changes, (i) amends certain funding conditions with respect to the remaining term loans available for borrowing under the Term Loan Agreement, (ii) increases the interest rate margin applicable to the term loans, (iii) increases the minimum interest rate and prepayment fees applicable to the term loans, and (iv) amends the minimum net revenue covenant under the Term Loan Agreement for certain reporting periods. As amended, term loans under the Term Loan Agreement bear interest at a floating rate based on an adjusted term SOFR (subject to a floor of 3.50%) for a one-month interest period, plus a margin of 6.75%. As amended, prepayments are subject to prepayment premiums of 3.00%, 2.00%, and 1.00% of the amount prepaid for prepayments made during years one, two, and three, respectively, after the date of the Term Loan Second Amendment.
The Revolving Loan Second Amendment, among other changes, (i) increases the minimum interest rate, (ii) increases the early termination fee applicable to the revolving loan facility, and (iii) amends the minimum net revenue covenant under the Revolving Loan Agreement for certain reporting periods. As amended, the loans under the Revolving Loan Agreement bear interest at a floating rate based on an adjusted term SOFR (subject to a floor of 3.50%) for a one-month interest period, plus a margin of 3.00%. As amended, an early termination or reduction of the revolving loan commitments is subject to a fee of 3.00%, 2.00%, and 1.00% of the revolving commitments so terminated or reduced.
Additional details of the Loan Agreements were previously disclosed in the Company’s Quarterly Report on Form 10-Q filed on May 12, 2023. The foregoing description of the Second Amendments does not purport to be complete and is qualified in its entirety by the terms and conditions of the Second Amendments, copies of which the Company will file with the Securities and Exchange Commission as exhibits to a forthcoming periodic financial report and are hereby incorporated herein by reference.
ITEM 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
The information related to the Second Amendments set forth in Item 1.01 above is incorporated herein by reference.
ITEM 5.07 Submission of Matters to a Vote of Security Holders.
On July 6, 2023, the Company held its 2023 Annual Meeting of Stockholders. Of the 29,716,199 shares of common stock outstanding as of May 12, 2023, the record date, 24,271,996 shares of common stock were represented at the meeting in person or by proxy, constituting approximately 81.68% of the outstanding shares of common stock entitled to vote and constituting a quorum for the transaction of business.
The stockholders of the Company voted on the following items at the meeting:
| | 1. | To elect two Class II directors to serve until the 2026 Annual Meeting of stockholders or until their respective successors are duly elected and qualified; and |
